These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19249410)

  • 1. The rationale and design of the FORomegaARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation.
    Macchia A; Varini S; Grancelli H; Nul D; Laffaye N; Ferrante D; Tognoni G; Doval HC;
    Am Heart J; 2009 Mar; 157(3):423-7. PubMed ID: 19249410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
    Pratt CM; Reiffel JA; Ellenbogen KA; Naccarelli GV; Kowey PR
    Am Heart J; 2009 Aug; 158(2):163-169.e1-3. PubMed ID: 19619690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.
    Bianconi L; Calò L; Mennuni M; Santini L; Morosetti P; Azzolini P; Barbato G; Biscione F; Romano P; Santini M
    Europace; 2011 Feb; 13(2):174-81. PubMed ID: 21059740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.
    Fetsch T; Bauer P; Engberding R; Koch HP; Lukl J; Meinertz T; Oeff M; Seipel L; Trappe HJ; Treese N; Breithardt G;
    Eur Heart J; 2004 Aug; 25(16):1385-94. PubMed ID: 15302102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.
    Saravanan P; Bridgewater B; West AL; O'Neill SC; Calder PC; Davidson NC
    Circ Arrhythm Electrophysiol; 2010 Feb; 3(1):46-53. PubMed ID: 20042769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study.
    Nodari S; Triggiani M; Campia U; Manerba A; Milesi G; Cesana BM; Gheorghiade M; Dei Cas L
    Circulation; 2011 Sep; 124(10):1100-6. PubMed ID: 21844082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI).
    Gold MR; Hoffmann E;
    Am Heart J; 2006 Aug; 152(2):231-6. PubMed ID: 16875902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.
    Macchia A; Grancelli H; Varini S; Nul D; Laffaye N; Mariani J; Ferrante D; Badra R; Figal J; Ramos S; Tognoni G; Doval HC;
    J Am Coll Cardiol; 2013 Jan; 61(4):463-468. PubMed ID: 23265344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
    Kowey PR; Reiffel JA; Ellenbogen KA; Naccarelli GV; Pratt CM
    JAMA; 2010 Dec; 304(21):2363-72. PubMed ID: 21078810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.
    Hohnloser SH; Connolly SJ; Crijns HJ; Page RL; Seiz W; Torp-Petersen C
    J Cardiovasc Electrophysiol; 2008 Jan; 19(1):69-73. PubMed ID: 18031520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
    Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
    Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.
    Mozaffarian D; Marchioli R; Macchia A; Silletta MG; Ferrazzi P; Gardner TJ; Latini R; Libby P; Lombardi F; O'Gara PT; Page RL; Tavazzi L; Tognoni G;
    JAMA; 2012 Nov; 308(19):2001-11. PubMed ID: 23128104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
    Gulizia M; Mangiameli S; Chiarandà G; Spadola V; Di Giovanni N; Colletti A; Bulla V; Circo A; Pensabene O; Vasquez L; Vaccaro I; Grammatico A;
    Europace; 2006 Apr; 8(4):302-5. PubMed ID: 16627459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.
    Adabag AS; Mithani S; Al Aloul B; Collins D; Bertog S; Bloomfield HE;
    Am Heart J; 2009 May; 157(5):913-8. PubMed ID: 19376321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion.
    Naji F; Suran D; Kanic V; Vokac D; Sabovic M
    Med Sci Monit; 2009 Sep; 15(9):CR494-8. PubMed ID: 19721402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm.
    Cohen M; Naccarelli GV
    J Cardiovasc Electrophysiol; 2008 Aug; 19(8):885-90. PubMed ID: 18373600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.
    Kirkegaard E; Svensson M; Strandhave C; Schmidt EB; Jørgensen KA; Christensen JH
    Br J Nutr; 2012 Mar; 107(6):903-9. PubMed ID: 21791142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
    Fogari R; Derosa G; Ferrari I; Corradi L; Zoppi A; Lazzari P; Santoro T; Preti P; Mugellini A
    Am J Hypertens; 2008 Sep; 21(9):1034-9. PubMed ID: 18566593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
    Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.